en.Wedoany.com Reported - WuXi Biologics (2269.HK) announced that its formulation plant at the Contract Research, Development and Manufacturing Organization (CRDMO) center in Singapore has topped out. The facility is expected to produce approximately 100 million units of pre-filled syringes and vials annually.

Located in the Tuas Biomedical Park, the center covers an area of 13.5 hectares and is the first facility of its kind in Singapore. The formulation plant has a building area of approximately 30,000 square meters and is equipped with three pre-filled syringe production lines and two vial production lines for liquid and lyophilized products, covering multiple dosage forms for both clinical and commercial stages. The facility also integrates solar panels and an energy monitoring and analysis system, and is expected to commence operations in 2027.

Once operational, the formulation plant will be designed in accordance with the latest international market requirements, becoming a key formulation production base for WuXi Biologics and adding 120,000 liters of capacity to the company's global network. WuXi XDC, a subsidiary of WuXi Biologics, achieved mechanical completion of its Singapore ADC production facility on the same site in 2025. The active pharmaceutical ingredient (API) plant at the center is currently still in the design phase.

Dr. Chen Zhisheng, CEO of WuXi Biologics, stated that this milestone enhances the company's ability to provide resilient and geographically diversified supply chains for global biopharmaceutical companies, while the company is also committed to contributing to the local community and biopharmaceutical industry in Singapore.

As of 2025, WuXi Biologics' global manufacturing footprint covers China, the United States, Ireland, Germany, and Singapore, operating a total of 24 API facilities and 18 formulation facilities. The company has passed 46 global regulatory inspections, including 22 conducted by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), achieving a 100% pass rate.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com